View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 3, 2017

Paratek’s Phase III trial of omadacycline shows positive outcome in CABP treatment

US-based biopharmaceutical firm Paratek Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of omadacycline to treat community-acquired bacterial pneumonia (CABP) patients.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

US-based biopharmaceutical firm Paratek Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of omadacycline to treat community-acquired bacterial pneumonia (CABP) patients.

Omadacycline is an investigational oral and intravenous (IV) broad spectrum antibiotic currently being designed for use as empiric monotherapy for patients with community-acquired bacterial infections.

The results from the trial indicated that all the US Food and Drug Administration (FDA) primary and secondary endpoints, as well as European Medical Agency (EMA) co-primary endpoints have been met.

The global, randomised, double-blind, active-controlled, multi-centre Phase III OPTIC trial evaluated the safety and efficacy of once-daily, IV-to-oral omadacycline compared to IV-to-oral moxifloxacin in 774 adult patients.

Paratek chairman and chief executive officer Michael Bigham said: “This successful study demonstrates the potential of omadacycline to treat community-acquired bacterial pneumonia, a significant and serious health issue.

"This successful study demonstrates the potential of omadacycline to treat community-acquired bacterial pneumonia, a significant and serious health issue."

“This Phase III study in pneumonia, along with our previously announced successful Phase III study in skin infections, satisfy the regulatory filing requirements of our special protocol assessment with the FDA."

Omadacycline has met the primary endpoint of statistical non-inferiority (NI) and secondary endpoints at the post-treatment evaluation (PTE) visit five to ten days post-treatment completion.

The drug was also found to be safe and well-tolerated with a high response rate, and met statistical non-inferiority compared to moxifloxacin.

Paratek plans to submit a new drug application (NDA) to the FDA in the first quarter of next year and to EMA late next year.


Image: Lungs with community-acquired pneumonia. Photo: courtesy of Jtechr/Wikipedia.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena